Muge Cevik

Muge Cevik

Auto-generated profile, based on publicly available information

Muge Cevik

University of St Andrews

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in BMJ
Verified
Journal Article
Closed access
PDF file
MCMuge Cevik
Muge Cevik
KKKrutika Kuppalli
Krutika Kuppalli
JKJason Kindrachuk
Jason Kindrachuk
MPMalik Peiris
Malik Peiris

1 July 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MCM. Cevik
M. Cevik
CBC.G.G. Bamford
C.G.G. Bamford
AHA. Ho
A. Ho

1 February 2018 in The Lancet
Verified
Journal Article
Open access
GTGuy E Thwaites
Guy E Thwaites
MSMatthew Scarborough
Matthew Scarborough
ASAlexander Szubert
Alexander Szubert
ENEmmanuel Nsutebu
Emmanuel Nsutebu
RTRobert Tilley
Robert Tilley
DJDebbie Johnson
Debbie Johnson
Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. UK National Institute for Health Research Health Technology Assessment.

3 September 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MLMeira Levinson
Meira Levinson
MCMuge Cevik
Muge Cevik
MLMarc Lipsitch
Marc Lipsitch
For the past 6 months, policymakers and the U.S. public have weighed economic against public health considerations in debating what limits to set on individual and collective behaviors in attempting to control the Covid-19 pandemic. As fall approaches, attention has turned to a third pillar of a pandemic-resilient society: schools.1 Under ordinary circumstances, about 40 million children would be entering prekindergarten through 8th-grade classrooms this year, including nearly 27 million students in grades pre-K through 5.2,3 Until these children physically return to school full time, many will lose out on essential educational, social, and developmental benefits; neither the economy nor the health care system will be able to return to full strength given parents’ caretaking responsibilities4; and profound racial and socioeconomic injustices will be further exacerbated.5 We believe that safely reopening schools full-time for all elementary school children should therefore be a top national priority.

1 April 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
XQXueting Qiu
Xueting Qiu
ANAli Ihsan Nergiz
Ali Ihsan Nergiz
AMAlberto Enrico Maraolo
Alberto Enrico Maraolo
IBIsaac I. Bogoch
Isaac I. Bogoch
NLNicola Low
Nicola Low
MCMuge Cevik
Muge Cevik

25 February 2021 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
EAEmma K. Accorsi
Emma K. Accorsi
XQXueting Qiu
Xueting Qiu
EREva Rumpler
Eva Rumpler
LKLee Kennedy-Shaffer
Lee Kennedy-Shaffer
RKRebecca Kahn
Rebecca Kahn
MLMarc Lipsitch
Marc Lipsitch
In response to the coronavirus disease (COVID-19) pandemic, public health scientists have produced a large and rapidly expanding body of literature that aims to answer critical questions, such as the proportion of the population in a geographic area that has been infected; the transmissibility of the virus and factors associated with high infectiousness or susceptibility to infection; which groups are the most at risk of infection, morbidity and mortality; and the degree to which antibodies confer protection to re-infection. Observational studies are subject to a number of different biases, including confounding, selection bias, and measurement error, that may threaten their validity or influence the interpretation of their results. To assist in the critical evaluation of a vast body of literature and contribute to future study design, we outline and propose solutions to biases that can occur across different categories of observational studies of COVID-19. We consider potential biases that could occur in five categories of studies: (1) cross-sectional seroprevalence, (2) longitudinal seroprotection, (3) risk factor studies to inform interventions, (4) studies to estimate the secondary attack rate, and (5) studies that use secondary attack rates to make inferences about infectiousness and susceptibility.